Pharmacy Drugs
Recent Posts
- Malignant Brain Tumors: Chemotherapy Alone Is Just As Effective As Radiation / New Positive Prognostic Factor Found
- Positive Interim Data From Minnow Medical Peripheral Artery Disease Trial Presented At TCT 2009 Conference
- Intercept Pharmaceuticals’ FXR Agonist INT-747 Meets Primary Endpoint In A Phase II Clinical Trial In Type 2 Diabetic Patients
- Largest Clinical Trial To Test Benefits Of Aspirin In Australia
- University Of Florida To Receive $29.5 Million In Recovery Act Funds To Begin Study Of Whether Exercise Prevents Disability In Older Adults
Random Posts
- BYETTA Approved For Expanded Use As First-Line Treatment For Type 2 Diabetes
- FDA Device Chief Quits as Ethics Probe Targets CDER Director
- New Updates To AHA/ACC/SCAI Clinical Guidelines Recommend Treatment With Effient(R) For Patients With Acute Coronary Syndromes Managed With PCI
- Investigational Dual Orexin Receptor Antagonist Almorexant Meets Primary Endpoint In Two-week Phase III Study Of Primary Insomnia
- Researchers Identify Possible Imaging Method To Stratify Breast Cancer Without Biopsy
- Full Testing Recommended For Medicinal Products Susceptible To 'Dose Dumping'
- Hope For Advanced Thymic Cancer Patients: New International Study Targets Rare Cancer
- Intra-Cellular Therapies Announces The Results Of A Phase I PET Study For ITI-007 For The Treatment Of Schizophrenia And Other Psychiatric Disorders
- Actelion Provides Update On BUILD-3 Study In Idiopathic Pulmonary Fibrosis
- NPA Responds To Study On Care Homes' Use Of Medicines
Altus Pharmaceuticals Reports Dosing First Patient In A Phase 2 Trial Of ALTU-238 For Pediatric Growth Hormone Deficiency
Posted by: admin in Pharmacy Drugs on June 15th, 2009
Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announced that patient dosing in its Phase 2 trial for ALTU-238 in growth hormone deficiency pediatric subjects began on June 2, 2009. ALTU-238 is a long-acting, extended-release formulation of recombinant human growth hormone (rhGH, somatropin), which is being developed utilizing Altus’ proprietary protein crystallization technology. ALTU-238 is a ready-to-use liquid suspension of crystallized rhGH that preserves the structure of the rhGH molecule without the need for pegylation, polymerization, or encapsulation and enables administration through a fine gauge needle. The Phase 2 ALTU-238 pediatric trial is being conducted in approximately 18 clinical sites in the U.S. and targets enrolling 36 growth hormone deficient pediatric patients. ALTU-238 has been studied in a series of Phase 1 and Phase 2 studies in healthy and GH deficiency adults.
“Moving this pediatric trial forward is an important step in re-establishing the value of the ALTU-238 program and Altus,” stated Dr. Georges Gemayel, President and Chief Executive Officer of Altus Pharmaceuticals. “This Phase 2 pediatric trial is the fifth clinical study to evaluate ALTU-238. Previous ALTU-238 studies have demonstrated pharmacokinetic and pharmacodynamic (PK/PD) profiles that are supportive of and consistent with a once-per-week dosing regimen.”
The Company is also announcing that Kenneth Attie, M.D., Vice President of Clinical Development and Medical Affairs at Altus Pharmaceuticals, will be presenting results from a key Phase 1 study in the ALTU-238 development program at The Endocrine Society’s 91st Annual Meeting in Washington, D.C. at the Washington Convention Center on Wednesday, June 10, 2009. The Endocrine Society’s Annual Meeting (ENDO) is a leading forum for physicians and other clinicians who treat endocrine conditions, including growth hormone disorders.
Dr. Ken Attie stated, “As we present this Phase 1 data and start the Phase 2 trial, we believe ALTU-238 has the opportunity to demonstrate its unique advantages compared to daily growth hormone products as well as the other long-acting growth hormone candidates that are in development.”
Dr. Attie will be presenting a poster entitled, “Pharmacokinetic, Pharmacodynamic and Safety Results of ALTU-238, a Long-Acting, Crystalline Recombinant Human Growth Hormone, in Healthy Adults.” The ALTU-238 Phase 1 trial evaluated the safety and PK/PD profile of a single dose of weekly ALTU-238 compared to seven injections of daily growth hormone. ALTU-238 was well tolerated in the one-week study that included 36 healthy, adult subjects. In addition, the Phase 1 PK/PD data is consistent with prior ALTU-238 clinical studies that supported a once-per-week dosing regimen. The Phase 1 trial results also indicate that the ALTU-238 material, produced at the current increased manufacturing scale, performs similarly to the material used in previous ALTU-238 studies.
Source
Altus Pharmaceuticals Inc.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.